Long-acting Insulin Analogues (Insulin Glargine or Determir) and Continuous Subcutaneous Insulin Infusion in the Treatment of Type 1 Diabetes Mellitus in the Paediatric Population

Articles in the same Issue

1. TABLE OF CONTENTS
2. Foreword
3. Ethical and Legal Implications of the Use of Molecular Biology in the Clinic
4. Endocrine Disrupters
5. Cell Replacement in Type 1 Diabetes Mellitus
6. Endocrine Complications in Children and Adolescents with Cancer
7. Rational Therapeutic Use of Growth Hormone
8. Long-acting Insulin Analogues (Insulin Glargine or Determir) and Continuous Subcutaneous Insulin Infusion in the Treatment of Type 1 Diabetes Mellitus in the Paediatric Population
9. Anorexia Nervosa: An Endocrine Focus and Procedure Guidelines
10. Molecular Basis of Human Obesity
11. Hyperandrogenism and Excess Weight Gain
12. Clinical Evaluation and Health Care in Childhood and Adolescent Obesity
13. Genetically Determined Gonadal Tumours in Children
14. Follow-up and Risk of Tumors in Overgrowth Syndromes
15. Multiple Endocrine Neoplasia: Paediatric Perspective
16. Epidemiology and Impact of Iodine Deficiency in Pediatrics
17. Pathophysiology of Thyroid Hormone Deficiency During Fetal Development
18. Neonatal Iodine Deficiency: Clinical Aspects
19. Psycho-intellectual Development of 3 Year-old Children with Early Gestational Iodine Deficiency
20. SELECTED ORAL ABSTRACTS. SELECTED POSTER ABSTRACTS